Cyclacel Pharmaceuticals ... (CYCC)
NASDAQ: CYCC
· Real-Time Price · USD
6.37
-0.40 (-5.91%)
At close: Sep 11, 2025, 3:59 PM
Cyclacel Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
Revenue | 43K | 420K | n/a | n/a |
Cost of Revenue | n/a | n/a | 32K | 43K |
Gross Profit | 43K | 420K | -32K | -43K |
Operating Income | -12M | -25.45M | -27.66M | -22.94M |
Interest Income | 12K | 266K | 210K | 16K |
Pretax Income | -11.99M | -25.55M | -25.91M | -22.18M |
Net Income | -11.21M | -22.55M | -21.2M | -18.89M |
Selling & General & Admin | 5.39M | 6.72M | 7.38M | 7.46M |
Research & Development | 6.66M | 19.16M | 20.27M | 14.93M |
Other Expenses | n/a | n/a | n/a | n/a |
Operating Expenses | 12.05M | 25.87M | 27.66M | 22.39M |
Interest Expense | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a |
Cost & Expenses | 12.05M | 25.87M | 27.66M | 22.39M |
Income Tax Expense | -782K | -3M | -4.72M | -3.85M |
Shares Outstanding (Basic) | 8.31M | 797.63K | 750.38K | 595.07K |
Shares Outstanding (Diluted) | 8.31M | 797.63K | 750.38K | 595.07K |
EPS (Basic) | -1.36 | -28.67 | -28.5 | -32.1 |
EPS (Diluted) | -1.36 | -28.67 | -28.5 | -32.1 |
EBITDA | -12M | -25.42M | -27.62M | -22.69M |
EBIT | -12M | -25.45M | -27.66M | -22.73M |
Depreciation & Amortization | 6K | 31K | 32K | 43K |
Source: Financial Modeling Prep. Financial Sources.